Peptone Raises $40 Million to Revolutionize Drug Discovery with Supercomputing

Peptone, a molecular computational physics company based in London, has raised $40 million in Series A funding led by F-Prime Capital

Peptone aims to revolutionize biopharmaceutical research and development by applying advanced biophysics, atomic-level experimental approaches, cutting-edge supercomputing, and machine learning to its drug discovery methods

Other investors in the round include Bessemer Venture Partners, Walden Catalyst Ventures, and existing investors Hoxton Ventures and dRX Capital, the venture arm of Novartis.